steelman - Condolences on your loss.

Welcome to the RVX board.

Resverlogix(RVX) is in the process of developing a whole new area of science, epigenetics, one level above genes. Their lead candidate is a compound call apabetalone, sometimes referred to as RVX208. Zenith Capital Corp was spun out of RVX around 2013 and owns a royalty on any drugs that are developed and sold from both the Resverlogix and Zenith intellectual property portfolios.

Zenith has its own board here on Agoracom.com under Zenith Epigenetics. At this time Zenith is focused on there lead candidate ZEN3694 for both prostate cancer and Tripple Negative Breast Cancer under the banner of Zenith Epigenetics Limited, a wholly owned entity of Zenith Capital Corp. In short it looks like the patients in the prostate cancer trial just wrapped up, would live up to 21 months longer than otherwise expected to, at least with the last information that has been made available. They should now be in possession of the data for the first 30 days of the TNBC trial at this time although they have not posted or presented those results. Zenith has about 1500 molecules in their in their intellectual property portfolio. For more info on Agoracom.com about Zenith please visit their board.

RVX has just completed a Phase III trial, BETonMACE for their lead candidate, apabetalone for cardiovascular disease in diabetics. They failed to meet the Top Line requirements to apply for full drug registration. Although they failed this trial it was close and as golfyeti mentioned it seemed to be more of a trial that was underpowered (not enough patients in a trial that was on for to short a period of time), than it was about a bad drug. The safety profile for this chronic use drug was quite good. What they found is that apabetalone works best in diabetic patients on an SGLT2 drug that had low functioning kidneys and cognitive impairment. There is about 10 million people in the G8 countries that fit that bill so there is potential for greater than $5 billion in annual sales(maybe as high as $20 billion in annual sales) which puts the drug in a category called mega blockbuster. In short that means don't give up to easily.

RVX has about 2500 molecules in their IP portfolio and holds about 7 patents at this time. As well as cardiovascular issues apabetalone may have a positive effect for chronic kidney disease, cognitive impairment, diabetes, HIV, macular degeneration and arthritis along with a few more ailments that I have failed to remember. There are compounds in different stages of development for both MD and MS as well.

As for what you do with the shares...it's the billion dollar question that all investors are asking themselves at this time. First and foremost this is a biotech development company which fits in the highest risk category of any single type of shares to invest in. If the science works your a hero and win big. If the science fails your a chump and lose big. It is the type of holding you should have as part of a portfolio and not one off. Having said that most of the heavy lifting has already been done for apabetalone in the past 20 years or so. It is shown to be safe for chronic use and in certain areas has some amazing potential, but needs more study, which takes more money. The president of the company has said on at least 3 occasions in the last couple of months that they are in discussions with large pharma companies about partnership arrangements to continue the development of apabetalone. We should hear about those talks and the developments in the next 3 to 6 months, hopefully tomorrow though.

The value of the shares can and do change very rapidly with scientific results and the ability of the company to pay its bills. There is no current market for the ZCC shares as it is a none trading public company. If they are held in an RSP or TSFA it may be a problem for the estate but a number of posters on the board will have suggestions for you on how to deal with that if it's an issue.

Bottom line, RVX could be worth $20 a share or $ .05 and share in the near future. Personally I'm leaning toward $12 to $16 in the next 6 months.

Good luck

All in my opinion, do your own due diligence.

tada